IMATHERA’s research projects are focused on four major areas: oncology, pulmonary fibrosis, cardiovascular disease, and preclinical imaging methodology.
Together, let’s overcome cancer.
About IMATHERa
For many years now, nuclear medicine has been a crucial tool both for the detection of cancers using molecular imaging and for the treatment of tumors using targeted radionuclide therapy.
The anti-cancer center Centre Georges-François Leclerc (CGFL) of Dijon has technical expertise in preclinical and clinical imaging, as well as translational research capabilities through its Nuclear Medicine Department which hosts the CGFL’s lab for diagnostic IMAging and radioTHERanostics (IMATHERa). In this context, the IMATHERa team aims to become a reference center for the preclinical development of innovative theranostic strategies in oncology, pulmonary fibrosis, cardiovascular diseases and preclinical imaging methodology.
Thanks to its strategic location on the Dijon university campus and its membership of the GIE Pharm’image®, the IMATHERa team works with a number of highly specialized local partners in complementary fields, ranging from the design of molecules for radiotheranostics (ICMUB, CheMatech) to the processing of patient images (CGFL, CHU Dijon) and preclinical validation (Oncodesign, IMATHERa), providing a unique field of local expertise. Its proximity to eminent research centers (INSERM, UB, CNRS) and clinicians means that IMATHERa is part of a translational research approach dedicated to patients.
Services
>
Looking to develop and evaluate a new diagnostic compound using imaging ?
>
Need imaging to assess the biodistribution of your molecule ?
>
Aiming to generate and evaluate a novel targeted radionuclide therapy molecule ?
Discover our expertise from chemistry to biological evaluation for the development of your theranostic solution.
IMATHERA has been awarded ANR funding for a 3-year research project on RIT in HER2-low breast cancer.
IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Alexandre DIAS (IMATHERA, CGFL) obtained funding through the young researcher programm of ANR of €324,000 over 3 years (2024-2027). This project entitled “Improved imaging and therapy of HER2-low breast cancer” (EITHER2BC) aims at developing theranostic probes (combining properties for diagnosis and therapy)[…]
IMATHERA has been awarded INCA funding for a 3-year research project on FGS in colon and pancreatic cancers.
IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the INCA of €130,000 over 3 years (2024-2027) as partner of a global INCA project entitled “Development of bimodal antibodies targeting colorectal and pancreatic tumors for fluorescenceguided surgery application”. This project is led by Dr Catherine[…]
IMATHERA has been awarded FEDER funding for a 5-year research program on RIT in metastatic colon and gastric cancers.
IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Drs Alexandre COCHET and Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the FEDER of 3.6 M€ over 5 years (2023-2028). This project entitled “moleCular radiOtherapy for Metastatic ColorEcTal and Gastric cancErs” (COMETE) aims at developing theranostic probes (for RIT and associated companion diagnostics)[…]
IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) was present at the “5ème Journées Scientifiques du GDR Agents d’Imagerie Moléculaire (GDR AIM)” in Paris. Romain Fontaine-Tuffery (ICMUB – UMR CNRS 6302/CGFL) presented his research work as part of the EQUIPEX IMAPPI (ANR-10-EQPX-0005) on the synthesis of fluorinated metal porphyrin[…]
IMATHERa (CGFL, Dr Bertand Collin, ICMUB – UMR CNRS 6302) was present at the “Journées de recherche respiratoires (J2R)” in Tours. Dr Alexandre Dias (CGFL) presented his research work as part of the HYMAGE-IPF project (ANR-20-CE17-0005) on the development of a theranostic strategy targeting Gp96 in pulmonary fibrosis. This work, under the direction of Dr Pierre-Simon Bellaye (CGFL),[…]
IMATHERa (CGFL) was present at the European Congress of Nuclear Medicine (EANM) in Vienna. Drs Alan Courteau and Bertrand Collin (CGFL / ICMUB – UMR CNRS 6302) presented their research work part of the EQUIPEX IMAPPI (ANR-10-EQPX-0005) program on preclinical multi-animal PET/MRI imaging and preclinical theranostic PET imaging of CD30-positive cancers with [Zr89]Zr-DFO-Brentuximab vedotin, respectively.
IMATHERA has been awarded ANR funding for a 3-year research project on RIT in HER2-low breast cancer.
IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Alexandre DIAS (IMATHERA, CGFL) obtained funding through the young researcher programm of ANR of €324,000 over 3 years (2024-2027). This project entitled “Improved imaging and therapy of HER2-low breast cancer” (EITHER2BC) aims at developing theranostic probes (combining properties for diagnosis and therapy)[…]
IMATHERA has been awarded INCA funding for a 3-year research project on FGS in colon and pancreatic cancers.
IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Dr Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the INCA of €130,000 over 3 years (2024-2027) as partner of a global INCA project entitled “Development of bimodal antibodies targeting colorectal and pancreatic tumors for fluorescenceguided surgery application”. This project is led by Dr Catherine[…]
IMATHERA has been awarded FEDER funding for a 5-year research program on RIT in metastatic colon and gastric cancers.
IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) through Drs Alexandre COCHET and Pierre-Simon BELLAYE (IMATHERA, CGFL) obtained funding through the FEDER of 3.6 M€ over 5 years (2023-2028). This project entitled “moleCular radiOtherapy for Metastatic ColorEcTal and Gastric cancErs” (COMETE) aims at developing theranostic probes (for RIT and associated companion diagnostics)[…]
IMATHERA (CGFL, Dr Bertand Collin, Associate Professor, ICMUB – UMR CNRS 6302) was present at the “5ème Journées Scientifiques du GDR Agents d’Imagerie Moléculaire (GDR AIM)” in Paris. Romain Fontaine-Tuffery (ICMUB – UMR CNRS 6302/CGFL) presented his research work as part of the EQUIPEX IMAPPI (ANR-10-EQPX-0005) on the synthesis of fluorinated metal porphyrin[…]
IMATHERa (CGFL, Dr Bertand Collin, ICMUB – UMR CNRS 6302) was present at the “Journées de recherche respiratoires (J2R)” in Tours. Dr Alexandre Dias (CGFL) presented his research work as part of the HYMAGE-IPF project (ANR-20-CE17-0005) on the development of a theranostic strategy targeting Gp96 in pulmonary fibrosis. This work, under the direction of Dr Pierre-Simon Bellaye (CGFL),[…]
IMATHERa (CGFL) was present at the European Congress of Nuclear Medicine (EANM) in Vienna. Drs Alan Courteau and Bertrand Collin (CGFL / ICMUB – UMR CNRS 6302) presented their research work part of the EQUIPEX IMAPPI (ANR-10-EQPX-0005) program on preclinical multi-animal PET/MRI imaging and preclinical theranostic PET imaging of CD30-positive cancers with [Zr89]Zr-DFO-Brentuximab vedotin, respectively.
Warning: Undefined variable $items_link in /home/mnrvzed/imathera/content/themes/cgfl/wazablocks/items/views/slider-partner.php on line 99
Need information ?
Leave you contact info below and we will get back to you shortly.
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
